These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32815157)

  • 1. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches.
    Kukharsky MS; Skvortsova VI; Bachurin SO; Buchman VL
    Med Res Rev; 2021 Sep; 41(5):2804-2822. PubMed ID: 32815157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
    Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
    J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review.
    Potenza RL; Armida M; Popoli P
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
    Deeb O; Nabulsi M
    Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs.
    Okano H; Yasuda D; Fujimori K; Morimoto S; Takahashi S
    Trends Pharmacol Sci; 2020 Feb; 41(2):99-109. PubMed ID: 31926602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.
    Fiscon G; Conte F; Amadio S; Volonté C; Paci P
    Neurotherapeutics; 2021 Jul; 18(3):1678-1691. PubMed ID: 33987813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis.
    Loeffler JP; Picchiarelli G; Dupuis L; Gonzalez De Aguilar JL
    Brain Pathol; 2016 Mar; 26(2):227-36. PubMed ID: 26780251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyotrophic lateral sclerosis. Recent advances in pathogenesis and therapeutic trials.
    Mitsumoto H; Hanson MR; Chad DA
    Arch Neurol; 1988 Feb; 45(2):189-202. PubMed ID: 3277599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS).
    Bartus RT; Bétourné A; Basile A; Peterson BL; Glass J; Boulis NM
    Neurobiol Dis; 2016 Jan; 85():11-24. PubMed ID: 26459114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studying ALS: Current Approaches, Effect on Potential Treatment Strategy.
    Ustyantseva EI; Medvedev SP; Zakian SM
    Adv Exp Med Biol; 2020; 1241():195-217. PubMed ID: 32383122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational therapeutic strategies in amyotrophic lateral sclerosis.
    Ryu H; Ferrante RJ
    Mini Rev Med Chem; 2007 Feb; 7(2):141-50. PubMed ID: 17305588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic development in amyotrophic lateral sclerosis.
    Bucchia M; Ramirez A; Parente V; Simone C; Nizzardo M; Magri F; Dametti S; Corti S
    Clin Ther; 2015 Mar; 37(3):668-80. PubMed ID: 25666449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives.
    Ralli M; Lambiase A; Artico M; de Vincentiis M; Greco A
    Isr Med Assoc J; 2019 Jul; 21(7):438-443. PubMed ID: 31507117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies.
    Gittings LM; Sattler R
    Fac Rev; 2020; 9():12. PubMed ID: 33659944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets.
    Bosco DA; Landers JE
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):779-90. PubMed ID: 20942785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.
    Festoff BW; Suo Z; Citron BA
    CNS Drugs; 2003; 17(10):699-717. PubMed ID: 12873154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis.
    Costa J; Gomes C; de Carvalho M
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):764-78. PubMed ID: 20942786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.